Definium Therapeutics reported positive Phase 3 results for its LSD candidate demonstrating strong antidepressant effects, marking a significant clinical trial readout for psychedelic psychiatry.
Definium Therapeutics reported positive Phase 3 results for its LSD-based candidate DT120 in major depressive disorder, indicating significant improvement in depression symptoms.
Definium Therapeutics reported positive Phase 3 results for DT120, an LSD-based therapy for major depression, showing significant symptom reduction compared to placebo.
A large cohort study suggests that single early prescriptions of benzodiazepines after mass trauma do not increase PTSD risk, challenging the blanket guideline against their use for acute distress prevention.
A large population-wide cohort study addresses the long-standing clinical question of whether post-trauma benzodiazepine prescribing increases subsequent PTSD risk, leveraging a natural experiment to mitigate confounding by indication.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Mar 31 – Jun 22)
- Consider that a single early prescription of benzodiazepines after mass trauma does not appear to increase subsequent PTSD risk, challenging the blanket guideline against their use for acute distress prevention.
- Initiating psychotherapy is associated with significant simplification of psychotropic regimens, including reduced polypharmacy and benzodiazepine use, without increasing total medication dose.
- Be aware that 7.8% of adults with dementia initiate CNS-active polypharmacy, primarily involving antidepressants and quetiapine, highlighting a need for prescribing guidelines to mitigate risks in this population.
- Secondary analysis suggests VR-assisted avatar therapy for auditory hallucinations works through context-specific confrontation processes rather than altering general emotion regulation strategies.
- ADHD medication use is associated with reduced risks of suicidality, criminality, drug misuse, and car accidents, supporting its protective benefits beyond symptom control.
- Definium Therapeutics reported positive Phase 3 results for DT120, an LSD-based therapy, showing significant depression symptom reduction compared to placebo in major depressive disorder.
- A large cohort study evaluates the risk of psychosis recurrence in adults with a history of psychosis who are prescribed psychostimulants or atomoxetine, warranting careful monitoring of this population.
Drug Development 1
Definium Therapeutics reports top-line Phase 3 data for its proprietary LSD formulation in a pivotal depression trial, signaling potential advancement of psychedelic therapeutics for major depressive disorder.
Diagnosis & Treatment 4
A clinical trial is recruiting to evaluate temporal interference stimulation targeting the dACC for treating negative and cognitive symptoms in schizophrenia.
A large Medicare cohort study reveals that 7.8% of adults with dementia initiate CNS-active polypharmacy, primarily involving antidepressants and quetiapine, highlighting a need for prescribing guidelines to mitigate risks.
A large real-world cohort study demonstrates that initiating psychotherapy is associated with significant simplification of psychotropic regimens (reduced polypharmacy and benzodiazepine use) without increasing total medication dose.
Secondary analysis of the CHALLENGE trial indicates that VR-assisted avatar therapy for auditory hallucinations does not work by altering self-reported emotion regulation strategies, suggesting clinicians should focus on context-specific confrontation processes rather than general emotional coping skills.
Journal Article 1
A study indicates that ADHD medication use is associated with reduced risks of suicidality, criminality, drug misuse, and car accidents.